Anti-Cancer Drug Linked to Tumor Shrinkage in Patients with Advanced Differentiated Thyroid Cancer
Thursday, October 27, 2011 - 16:30
in Health & Medicine
Researchers tested the effectiveness of lenvatinib in patients with advanced, progressive differentiated thyroid cancer (DTC) that does not respond to conventional radioiodine therapy. Data demonstrated a partial response in 45%-50% of the 58 patients enrolled in the study.